 |
| Sygen Pharmaceuticals and ORx Pharmaceuticals Announce Groundbreaking Joint Venture to Revolutionize Healthcare in Africa and Beyond Image credit: Daily Post Nigeria |
Formation of Sygen-ORx Biosciences Ltd
Sygen Pharmaceuticals Ltd, headquartered in Lagos, Nigeria, and ORx Pharmaceuticals Corporation, based in Ontario, Canada, have unveiled an exciting new joint venture named Sygen-ORx Biosciences Ltd. This partnership is set to transform healthcare by addressing pharmaceutical drug security challenges through innovative collaboration.
The Sygen Pharmaceuticals and ORx Pharmaceuticals Cooperation
Sygen Pharmaceuticals is renowned for its pioneering approach to healthcare in Africa, focusing on the development of high-quality medications and enhancing access to innovative treatments. The company has established itself as a trusted partner in driving positive change within Nigeria’s healthcare landscape. By combining its innovative spirit with ORx’s strengths, Sygen is poised to amplify its impact across the region.
ORx Pharmaceuticals, affiliated with the Toronto Institute of Pharmaceutical Technology, brings a wealth of expertise in drug development and commercialization. The company has consistently delivered transformative therapies across various therapeutic areas, earning its reputation as a leader in the pharmaceutical industry. ORx’s commitment to advancing medical science and improving patient care is well recognized, and it now joins forces with Sygen to bring its expertise to the joint venture.
Objectives and Focus of Sygen-ORx Biosciences Ltd
The joint venture aims to accelerate the development and commercialization of cutting-edge therapies to address unmet medical needs and improve healthcare access globally. Key focus areas include:
- Improved Formulations: Developing enhanced formulations of generic pharmaceuticals that have already proven their clinical efficacy and commercial success.
- Innovative Drug Discovery: Advancing innovative drug discovery programs into both regional and global markets.
- Increased Access in Africa: Reducing costs and increasing access to high-quality branded generic medicines in Africa.
In addition to these goals, Sygen and ORx will leverage their combined expertise in global drug discovery, research, development, and commercialization to accelerate open innovation, particularly in early-stage drug discovery.
Statements from Sygen and ORx Leadership
Dr. Alexander MacGregor, CEO of ORx Pharmaceuticals, emphasized the significance of this collaboration, stating, “Sygen-ORx Biosciences will build upon the foundation of excellence established by ORx and Sygen, ushering in a new era of healthcare innovation. With a shared commitment to scientific excellence and integrity, Sygen-ORx Biosciences is positioned to make a significant impact in the healthcare landscape, shaping the future of medicine for generations to come.”
Charles Ogunwuyi, CEO of Sygen Pharmaceuticals, echoed this sentiment, adding, “Collaboration is at the heart of our mission at Sygen Pharmaceuticals, and we are excited to embark on this transformative journey with ORx Pharmaceuticals. Together, as Sygen-ORx, we have the opportunity to amplify our impact and drive innovation in healthcare, ultimately improving the lives of patients in Africa and beyond.”
About ORx Pharmaceuticals
ORx Pharmaceuticals is at the forefront of innovative healthcare solutions, combining cutting-edge research, technology, and strategic partnerships to develop transformative treatments. With a portfolio of promising products in various stages of development, ORx is committed to revolutionizing healthcare and improving patient outcomes worldwide.
About Sygen Pharmaceuticals
Sygen Pharmaceuticals Ltd is an innovative life sciences company focused on improving patient outcomes in Africa. With a mission to enhance access to high-quality medicines, Sygen is committed to creating new drugs that address diseases with high unmet medical needs in the region, leveraging cutting-edge technology and collaboration with external partners.
For more information, visit [ORx Pharmaceuticals] and [Sygen Pharmaceuticals].
0 Comments